Generic Name and Formulations:
Palonosetron (as HCl) 0.075mg/1.5mL, 0.25mg/5mL; IV inj; contains mannitol.

Company:
Eisai Pharmaceuticals
Indications for ALOXI:
Prevention of acute nausea and vomiting due to initial and repeat courses of moderately and highly emetogenic chemotherapy in adults. Prevention of delayed nausea and vomiting due to initial and repeat courses of moderately emetogenic chemotherapy in adults. Prevention of acute nausea and vomiting due to initial and repeat courses of emetogenic chemotherapy, including highly emetogenic cancer chemotherapy, in children 1 month–<17yrs. Prevention of post-op nausea and vomiting for up to 24hrs after surgery in adults.

Adult Dose for ALOXI:
≥17yrs: give 30 mins prior to chemotherapy. 0.25mg IV as a single-dose over 30 secs. Post-op: give immediately before anesthesia induction. 0.075mg IV over 10 secs.

Children's Dose for ALOXI:
<1 month: not established. 1 month–<17yrs: give 30 mins prior to chemotherapy. 0.02mg/kg IV as a single-dose over 15 mins; max 1.5mg/dose.

Pharmacological Class:
Selective 5-HT3 receptor antagonist.

Warnings/Precautions:
Pregnancy (Cat.B). Nursing mothers: not recommended.

Adverse Reactions:
Headache, constipation, bradycardia, QT prolongation, diarrhea, dizziness, tachycardia, hypotension.

How Supplied:
Single-use vial (0.075mg/1.5mL)—5; (0.25mg/5mL)—1

注：本品有多个国家上市，购买以咨询为
包装规格
美国：0.075mg/1.5mL, 0.25mg/5mL
瑞士：ALOXI 0.25MG1 injectable
爱尔兰：ALOXI 0.25MG/5ML/AMP VIAL
欧洲共同体国家：ALOXI 0.25MG/5ML/VIAL